Bausch Health unit prevails in patent dispute

New Jersey court dismissed a suit regarding an oral antibiotic | Prior art invalidated plaintiff’s four patents.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Bausch Ireland fends off challenge to its cancer patent

12 September 2023 Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

Americas

Bausch targets Israeli firm in skin treatment dispute

22 June 2023 Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.

Americas

Pharma unit could get green light to launch IBS generic

2 August 2022 Dispute centres on Xifaxan, used to treat irritable bowel syndrome | ‘Significant hurdle’ cleared in bringing drug to market | Bausch wins partial victory after Alvogen subsidiary failed to show that patent claims were obvious.

More on this story

Big Pharma

Bausch Ireland fends off challenge to its cancer patent

12 September 2023 Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

Americas

Bausch targets Israeli firm in skin treatment dispute

22 June 2023 Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.

Americas

Pharma unit could get green light to launch IBS generic

More on this story

Big Pharma

Bausch Ireland fends off challenge to its cancer patent

12 September 2023 Pharma firm fails to show evidence to prove obviousness in rival’s patent | Treatment can be used to treat cancer as well as ulcerative colitis and asthma.

Americas

Bausch targets Israeli firm in skin treatment dispute

22 June 2023 Pharma company claims infringement of both patents that cover the blockbuster treatment | Generic version has been in motion since May last year.

Americas

Pharma unit could get green light to launch IBS generic